Clinical Trial Update: Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664). [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety, immune response, and efficacy of GSK's Epstein-Barr virus vaccine in Epstein-Barr virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• Epstein-Barr virus vaccine (Epstein-Barr virus vaccine)

Snippet

Sponsor: Henogen | Conditions: Epstein Barr Virus (EBV) Infection | Phase 2 | Status: COMPLETED